dm+d

Unassigned

New Medicines

Non-alcoholic steatohepatitis (NASH) with stage 4 liver fibrosis (cirrhosis)

Information

New molecular entity
Bristol-Myers Squibb
Bristol-Myers Squibb

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Nov 21Development discontinued after FALCON phase 2b programme failed to reach statistical significance for primary outcomes. BMS is exploring external opportunities for pegbelfermin.[3].

Category

A therapeutic protein that mimics biological properties of fibroblast growth factor-21
Fatty liver disease is divided into alcohol-related fatty liver disease, and non-alcoholic fatty liver disease (NAFLD). The only difference between the two is the alcohol. A threshold of <20 g of alcohol per day in women and <30 g in men is usually used to allow a diagnosis of NAFLD. When inflammation is present, this becomes non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. In Europe prevalence of NAFLD is 20-30% and NASH is 5% [1].
Non-alcoholic steatohepatitis (NASH) with stage 4 liver fibrosis (cirrhosis)
Subcutaneous